These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 1721912

  • 1. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
    Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H.
    J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
    [Abstract] [Full Text] [Related]

  • 2. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
    Seiffert D, Mimuro J, Schleef RR, Loskutoff DJ.
    Cell Differ Dev; 1990 Dec 02; 32(3):287-92. PubMed ID: 1711915
    [Abstract] [Full Text] [Related]

  • 3. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
    Ehrlich HJ, Keijer J, Preissner KT, Gebbink RK, Pannekoek H.
    Biochemistry; 1991 Jan 29; 30(4):1021-8. PubMed ID: 1703436
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
    Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Müller-Berghaus G.
    J Biol Chem; 1990 Oct 25; 265(30):18490-8. PubMed ID: 1698787
    [Abstract] [Full Text] [Related]

  • 6. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H.
    Blood; 1991 Sep 01; 78(5):1254-61. PubMed ID: 1715220
    [Abstract] [Full Text] [Related]

  • 7. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
    Keijer J, Ehrlich HJ, Linders M, Preissner KT, Pannekoek H.
    J Biol Chem; 1991 Jun 05; 266(16):10700-7. PubMed ID: 1709939
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
    Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H.
    J Biol Chem; 1990 Aug 05; 265(22):13029-35. PubMed ID: 1695900
    [Abstract] [Full Text] [Related]

  • 12. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.
    Schleef RR, Podor TJ, Dunne E, Mimuro J, Loskutoff DJ.
    J Cell Biol; 1990 Jan 05; 110(1):155-63. PubMed ID: 2104856
    [Abstract] [Full Text] [Related]

  • 13. Determinants of induction of increased synthesis of plasminogen activator inhibitor type-1 in human endothelial cells by t-PA.
    Fujii S, Sobel BE.
    Thromb Haemost; 1992 Feb 03; 67(2):233-8. PubMed ID: 1621243
    [Abstract] [Full Text] [Related]

  • 14. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells.
    Schleef RR, Wagner NV, Loskutoff DJ.
    J Cell Physiol; 1988 Feb 03; 134(2):269-74. PubMed ID: 3257967
    [Abstract] [Full Text] [Related]

  • 15. Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
    Norwitz ER, Snegovskikh V, Schatz F, Foyouzi N, Rahman M, Buchwalder L, Lee HJ, Funai EF, Buhimschi CS, Buhimschi IA, Lockwood CJ.
    Am J Obstet Gynecol; 2007 Apr 03; 196(4):382.e1-8. PubMed ID: 17403427
    [Abstract] [Full Text] [Related]

  • 16. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA, Owensby DA, Sobel BE, Schwartz AL.
    J Biol Chem; 1989 May 05; 264(13):7228-35. PubMed ID: 2540181
    [Abstract] [Full Text] [Related]

  • 17. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H.
    J Clin Invest; 1989 Aug 05; 84(2):647-55. PubMed ID: 2503541
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin.
    Owensby DA, Morton PA, Wun TC, Schwartz AL.
    J Biol Chem; 1991 Mar 05; 266(7):4334-40. PubMed ID: 1705551
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.